Proposed review of the 2023 scheme to control the cost of branded health service medicines

Proposed review of the 2023 scheme to control the cost of branded health service medicines The DHSC proposes to amend the statutory scheme controlling the cost of branded health service medicines. The consultation sets out proposed amendments in three main areas: increasing the allowed growth rate which will have the effect of changing the payment percentages; revising which sales of branded medicines are exempt from scheme payments; and a new approach to control spending on older branded medicines (the ‘lifecycle adjustment’). This consultation document seeks views on the proposals, particularly from the pharmaceutical industry and NHS patients. The consultation closes at 11am on 10 October 2023. Department of Health and Social Care